Hungary's largest drugmaker Gedeon Richter (RICHT: HB) has reached a deal with London-listed drugmaker Hikma Pharmaceuticals (LSE: HIK), out-licensing biosimilar denosumab for commercialization in the USA.
Denosumab is the active ingredient of US biotech giant Amgen’s (Nasdaq: AMGN) Prolia and Xgeva.
Richter is developing two products for the treatment of osteoporosis and fractures due to bone metastasis, respectively. These candidates are currently in global Phase I and Phase III clinical testing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze